Multiple Myeloma
Feature
Report details financial burden of blood cancers
Out-of-pocket spending for acute leukemia topped $5,100 in the year after diagnosis.
News
Molecule enhances PI activity in multiple myeloma
Researchers say they have identified a new class of protein disulfide isomerase (PDI) inhibitors that sensitize multiple myeloma (MM) cells to...
News
FDA clears portable hematology analyzer
The U.S.
From the Journals
ICYMI: Elotuzumab reduces progression risk in lenalidomide-refractory multiple myeloma
Patients had a significantly lower risk of progression or death when receiving elotuzumab plus pomalidomide and dexamethasone, compared with...
News
FDA approves elotuzumab with pom/dex in refractory myeloma
The approval is based on results from the phase 2 ELOQUENT-3 trial.
News
FDA approves elotuzumab combo for rel/ref MM
The U.S.
From the Journals
Haploidentical transplantation holds promise in relapsed myeloma
In multiple myeloma patients who have no matched donor, haploidentical allogeneic transplantation is feasible and has an acceptable rate of non-...
From the Journals
Genomic abnormalities shed light on racial disparity in myeloma
The researchers relied on genetic ancestry, rather than self-reported race, to evaluate myeloma disparities.
News
Palliative care guidelines relevant for hematologists, doc says
The latest edition of the national palliative care guidelines provides new clinical strategies relevant to hematology practice in the United...
News
Three gene types drive MM disparity in African Americans
Researchers say they may have determined why African Americans have a two- to three-fold increased risk of multiple myeloma (MM) compared to...
News
Better PFS may not mean better HRQOL
Cancer treatments that prolong progression-free survival (PFS) may not improve health-related quality of life (HRQOL), researchers reported in...